Transcriptomics

Dataset Information

0

An Engineered IL-15 Cytokine Mutein Fused to an Anti-PD1 Antibody Improves Intratumoral T Cell Function and Anti-tumor Immunity (human)


ABSTRACT: Background: Cancer Immunotherapy with cytokines has demonstrated clinical efficacy but is frequently accompanied with severe adverse events caused by excessive and systemic immune activation. Here, we addressed these challenges by engineering a fusion protein of a single, potency-reduced, IL-15 mutein and an anti-PD1 antibody (αPD1-IL15m). This immunocytokine is designed to deliver PD1-mediated avidity-driven IL-2/15 receptor stimulation preferentially to PD1-positive tumor-infiltrating lymphocytes (TILs) while reducing the natural preference of IL-15 for circulating peripheral NK or T cell Methods: We isolated human lymphocytes from resected hepatocellular carcinoma tissue and cultured these tumor-infiltrating lymphocytes (TILs) in vitro in the presence or absence of an PD1-targeted IL15 mutein, anti-PD1 antibody or IL-15 agonist. After 9 days, CD4+ TILs and CD8+ TILs were sorted by FACS and RNA of 3,000 to 150,000 cells was isolated. Results: The PD1-IL15 fusion cytokine enhanced pro-survival, proliferation and activation pathways in tumor-infiltrating CD4+ and CD8+ cells compared to untreated controls as well as to the combined treatment of single agents (anti-PD1 antibody and IL-15 agonist)

ORGANISM(S): Homo sapiens

PROVIDER: GSE157893 | GEO | 2021/05/25

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-07-13 | GSE160579 | GEO
| 2302069 | ecrin-mdr-crc
2024-03-15 | PXD045710 | Pride
2019-12-31 | E-MTAB-7278 | biostudies-arrayexpress
2013-01-03 | E-GEOD-43260 | biostudies-arrayexpress
2021-12-01 | GSE153383 | GEO
2014-07-01 | E-GEOD-55057 | biostudies-arrayexpress
2017-03-01 | GSE79127 | GEO
2024-10-28 | GSE261815 | GEO
2024-10-28 | GSE261380 | GEO